The US International Trade Commission (ITC) has ruled in favor of Masimo Corp’s patent infringement claim against Apple’s $17 billion smartwatch business, specifically related to blood oxygen level monitoring technology. The decision, effective on December 25, has led to speculation about potential White House intervention.
Apple announced a pause in the sales of its Series 9 and Ultra 2 smartwatches in the US due to a patent dispute over the blood oxygen feature technology. This move follows the ITC’s October order, which could prohibit Apple from importing its Apple Watches, citing violation of Masimo’s patent rights.
The ITC decision is currently under review by President Joe Biden until December 25. Apple is taking steps to comply if the ruling stands, with sales paused on its website from December 21 and at Apple retail locations after December 24. Models without the blood oxygen sensor, like the Apple Watch SE, remain unaffected.
The Office of the US Trade Representative, led by Ambassador Katherine Tai, is carefully considering all factors in the case. If not vetoed, the import ban would take effect on December 26. Masimo CEO Joe Kiani expressed openness to negotiating with Apple, emphasizing the importance of respecting intellectual property rights and maintaining public trust in the US patent system.
Apple’s Watch Woes: Sales Pause in US Amid Patent Clash with Masimo – Speculations Mount on Biden’s Intervention
Kanika Sharma is a Geopolitical Analyst and Editor at BigBreakingWire. She holds a Master's degree in History from the Central University of Punjab, with an academic background in qualitative research, text analysis, and historical frameworks. At BigBreakingWire, she analyzes global trade shifts, international policies, geopolitical developments, semiconductor supply chains, manufacturing policies, and sovereign industrial initiatives. Her work combines historical context with contemporary policy and macroeconomic analysis to explain complex global developments clearly and accurately.
Disclaimer: BigBreakingWire provides news and informational content for general educational purposes only. The information presented on this website does not constitute financial, investment, tax, or legal advice. Readers should consult qualified professionals before making any financial decisions. BigBreakingWire, its authors, and editors are not responsible for any financial losses or damages arising from the use of information on this site.
